| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14282d3a2e6e102c98227a9ea2d2deba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-56 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 |
| filingDate |
2020-03-06^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30ab3d72d864c324078cd8a8ad9582d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b91bfc4d36e193bf32838b1e88f3086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_650625e73e57edbe738df502103a010b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_392bbcf2f0dd88fcb0ebcfb38f9afaf0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b52df99a2262fa68ba4a998fa68e2f03 |
| publicationDate |
2020-07-30^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020239416-A1 |
| titleOfInvention |
Compounds as neurokinin-1 receptor antagonists and uses thereof |
| abstract |
The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779557-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11583510-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11766418-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400065-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11504347-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11602512-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11602513-B1 |
| priorityDate |
2018-07-26^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |